Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

lure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achiev
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... visión holística de l cuidado al ... trayecto   Royal Philips  ... debut europeo de IntelliSpace Cardiovascular , un sistema ... sofisticadas herramientas para acceder, analizar y compartir imágenes cardiovasculares ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... DIEGO, Sept. 19, 2011 Marshall Edwards, Inc. (Nasdaq: ... development of novel therapeutics targeting cancer metabolism, announced today that ... clinical trial of its lead drug candidate ME-143 in patients ... the Sarah Cannon Research Institute, is expected to enroll up ...
... (NYSE: LLY ) will bring one of its ... 2011 Annual Legislative Conference presented by the Congressional Black Caucus ... In attendance will be Eli Lilly and Company,s ... C onnected and E mpowered ...
Cached Medicine Technology:Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 4Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference 2
(Date:8/30/2015)... , ... August 31, 2015 , ... Negotiating an FDA ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/importholdcrisis , US authorities are holding ... products, and imports from India. , With alerts on an uptick and a new ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, the nonprofit ... , recently elected two new officers to serve on the organization’s Board of ... inspiring and teaching kids to cook real food with their families and help ...
(Date:8/30/2015)... Chicago, IL (PRWEB) , ... August 30, 2015 ... ... LLC is pleased to announce that Partner Daniel M. Kotin was recently ... within this exclusive organization constitutes the highest degree of peer recognition and outstanding ...
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers , a company that ... company is currently offering lice head checks for just $10, which is a significant ... 10% discount on their lice treatment products. “With kids returning to school, it is ...
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:InHealth Media Appoints New Global Communications Director 2
... a study published in the Archives of General Psychiatry suggest ... (a brain chemical related to mood), may serve as a ... disorder (PTSD) following a trauma. "One of the ... risk for developing the disorder following a trauma, while others ...
... 4 (HealthDay News) -- Many teens with autism rely on ... analyzed data from a 10-year study of more than 920 ... special education. The participants were aged 13 to 17 when ... of the teens with autism used a mental health service ...
... News) --,Dental injuries are all too common among young ... says. "Basketball and baseball are the two biggest ... are broken, displaced or knocked out teeth, and broken ... dentistry department at the University of Alabama at Birmingham, ...
... (HealthDay News) -- Having weight loss surgery before breast reduction ... procedures, according to a small new study. While there ... including reduced pain and increased ability to exercise -- women ... they lose large amounts of weight, Dr. Jeffrey Gusenoff and ...
... , FRIDAY, Sept. 2 (HealthDay News) -- Traffic safety should ... experts suggest. Each year in the United States, more than ... U.S. Centers for Disease Control and Prevention. "Kids who are ... see in the emergency department. Because of their height, when a ...
... familiar enough, but how deep do the implications ... School of Medicine at the University of Pennsylvania have ... bacteria of the human gut. In a study ... two distinct groups, called enterotypes, that were associated with ...
Cached Medicine News:Health News:The search for predictors of risk for PTSD 2Health News:Toothless Grins Are Only Cute on Babies 2Health News:Is Breast Reduction After Weight Loss Surgery Best? 2Health News:Traffic Safety Should Be Among First Lessons in New School Year 2Health News:Study linking gut microbe type with diet has implications for fighting GI disorders 2Health News:Study linking gut microbe type with diet has implications for fighting GI disorders 3
... worlds leading medical technology company and ... for more than a decade, introduces ... The ACT Plus System is a ... determine coagulation endpoints in whole blood, ...
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
... the Alcon OcuScan RxP Ophthalmic Ultrasound System, ... instrumentation. With improved auto modes and flexible ... to obtain measurements that are both accurate ... by providing high quality eye measurements in ...
... the Atlas+ HF ICD is designed to provide ... and quality of life. The Atlas+ HF ICD ... resynchronization therapy (CRT), and it packs its power ... physiologic-shaped can. In addition to its high energy, ...
Medicine Products: